NeuroVice, LLC, founded with a mission to revolutionize patient self-care through innovative medical device technology, focuses on enhancing the patient experience, particularly for those with neurological disorders. Their flagship product, PATI, is an FDA-cleared device designed to improve oral health during seizures, offering a safer and more effective alternative to traditional methods. NeuroVice aims to empower patients by providing tools that enable them to manage their health more independently.
The company has garnered attention for its groundbreaking approach and has attracted notable investors and advisors from the medical and tech industries. Key achievements include the FDA clearance of PATI, which marks a significant milestone in their mission to improve seizure management. NeuroVice's impact is evident in its commitment to addressing a critical need in the epilepsy community, ultimately enhancing the quality of life for patients worldwide.
